By targeting the MEK/ERK signaling pathway, Cobimetinib has been shown to inhibit metastasis in osteosarcoma and enhance the efficacy of doxorubicin in osteosarcoma models. This evidence concerns the gene MAP2K7 and osteosarcoma.